Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 600

Registration Number: NCT00003159

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Phase 3

Completed

Conditions: Endometrial Serous Adenocarcinoma
Stage III Uterine Corpus Cancer
Endometrial Adenosquamous Carcinoma
Endometrial Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation

Interventions: Drug: Doxorubicin Hydrochloride
Drug: Cisplatin
Biological: Filgrastim
Biological: Pegfilgrastim
Drug: Paclitaxel

First Posted Date: 2003-01-27

Last Posted Date: 2015-05-19

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 659

Registration Number: NCT00006011

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: docetaxel
Drug: doxorubicin hydrochloride
Drug: estramustine phosphate sodium
Drug: flutamide
Drug: ketoconazole
Drug: paclitaxel
Drug: releasing hormone agonist therapy
Drug: vinblastine sulfate

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-22

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 21

Registration Number: NCT00030654

Locations: 🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
🇺🇸
Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States

and more 75 locations

S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine
Drug: paclitaxel
Procedure: surgery

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 77

Registration Number: NCT00045630

Locations: 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States

and more 124 locations

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

Phase 1

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 40

Registration Number: NCT00003379

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 28 locations

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 48

Registration Number: NCT00003385

Locations: 🇺🇸
MBCCOP - Hawaii, Honolulu, Hawaii, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

and more 5 locations

Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer

Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-15

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT00004173

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-10

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 78

Registration Number: NCT00006248

Locations: 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 92 locations

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Other: laboratory biomarker analysis
Biological: bevacizumab

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 842

Registration Number: NCT00021060

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: paclitaxel
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT00025389

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy